RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Voyager Therapeutics Stock

Voyager Therapeutics Stocks 2024

Voyager Therapeutics Stocks

44.57 M

Ticker

VYGR

ISIN

US92915B1061

WKN

A143XJ

In 2024, Voyager Therapeutics had 44.57 M outstanding stocks, a 0% change from the 44.57 M stocks in the previous year.

The Voyager Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e44.57
2028e44.57
2027e44.57
2026e44.57
2025e44.57
2024e44.57
202344.57
202238.4
202137.7
202037.3
201935.9
201832.1
201726.8
201625.3
201525.7
201425.7
201325.7

Voyager Therapeutics shares outstanding

The number of shares was Voyager Therapeutics in 2023 — This indicates how many shares 44.569 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Voyager Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Voyager Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Voyager Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Voyager Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Voyager Therapeutics Aktienanalyse

What does Voyager Therapeutics do?

Voyager Therapeutics Inc is a biopharmaceutical company specializing in the development of gene therapy products. The company was founded in 2013 in Cambridge, Massachusetts. The main business model of Voyager Therapeutics involves the development, manufacturing, and marketing of gene therapy products. The company specializes in nervous system and ocular therapies and works closely with leading scientists and clinical institutes. Voyager Therapeutics has several business and research divisions: the Parkinson's Disease division, the Huntington's Disease division, and the Amyotrophic Lateral Sclerosis (ALS) division. The Parkinson's Disease division of Voyager Therapeutics focuses on developing gene therapies for the treatment of Parkinson's disease. The products being developed in this division aim to increase the amount of dopamine in the brain to alleviate the symptoms of Parkinson's disease. Parkinson's patients often suffer from symptoms such as tremors, stiffness, and lack of movement. The Huntington's Disease division of Voyager Therapeutics specializes in developing gene therapy products for the treatment of Huntington's disease. This disease is a hereditary condition that leads to the accumulation of toxic proteins in the brain, eventually causing neurological symptoms such as slow thinking and tremors. The ALS division of Voyager Therapeutics focuses on developing gene therapies for the treatment of Amyotrophic Lateral Sclerosis (ALS). ALS is a neurodegenerative disease in which nerve cells in the brain and spinal cord degenerate, leading to muscle weakness and atrophy. Voyager Therapeutics works closely with various institutions and companies to advance its research and development. Key collaboration partners include Sanofi Genzyme, Abbvie, Neurocrine Biosciences, and the University of Massachusetts Medical School. Some of Voyager Therapeutics' key products are currently in clinical trials or in development. The company is working on developing gene therapies for the treatment of Parkinson's disease, Huntington's disease, and ALS. One example of a product developed by Voyager Therapeutics is VY-AADC, a gene therapy for the treatment of Parkinson's disease. It is currently being tested in Phase 2 clinical trials. Another example is VY-HTT01, a gene therapy for the treatment of Huntington's disease. VY-HTT01 is currently in the preclinical development phase and is expected to be tested in clinical trials in the coming years. Overall, Voyager Therapeutics has a promising future in the gene therapy industry. The company has already achieved significant successes and continues to work intensively on developing new therapies to help people with neurological disorders. Voyager Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Voyager Therapeutics's Shares Outstanding

Voyager Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Voyager Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Voyager Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Voyager Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Voyager Therapeutics stock

How many stocks are there of Voyager Therapeutics?

The current number of stocks of Voyager Therapeutics is 44.57 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Voyager Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Voyager Therapeutics evolved in recent years?

The number of shares of Voyager Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Voyager Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Voyager Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Voyager Therapeutics pay?

Over the past 12 months, Voyager Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Voyager Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Voyager Therapeutics?

The current dividend yield of Voyager Therapeutics is .

When does Voyager Therapeutics pay dividends?

Voyager Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Voyager Therapeutics?

Voyager Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Voyager Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Voyager Therapeutics located?

Voyager Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Voyager Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Voyager Therapeutics from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Voyager Therapeutics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Voyager Therapeutics in the year 2023?

In the year 2023, Voyager Therapeutics distributed 0 USD as dividends.

In which currency does Voyager Therapeutics pay out the dividend?

The dividends of Voyager Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Voyager Therapeutics

Our stock analysis for Voyager Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Voyager Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.